Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction
AssigneeYeda Research and Development Co. Ltd.
InventorsBenjamin GEIGER, Eran ELINAV, Inna GROSHEVA
Life of this patent
Estimating the term…
Abstract
A method of treating a disease associated with intestinal barrier dysfunction in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent which downregulates the amount of glucose in intestinal cells, with the proviso that the disease is not Diabetes or obesity. Other agents for treating diseases associated with intestinal barrier dysfunction are also disclosed.
Claims19
A method of identifying agents useful for treating a disease associated with intestinal barrier dysfunction of a subject, the method comprising:
- (a) contacting tight junctions of epithelial cells with a disruptor agent that promotes disruption or destabilization of tight junctions of epithelial cells;
- and
- (b) contacting said tight junctions of epithelial cells with a test agent;
- and
- (c) analyzing the effect of said test agent on said tight junctions of epithelial cells, wherein when said test agent prevents disruption of, or stabilizes said tight junctions, it is indicative of said test agent being useful for treating the disease associated with intestinal barrier dysfunction of the subject.
A method of treating a disease associated with intestinal barrier dysfunction in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an agent which increases the amount and/or activity of at least one agent set forth in Table 2, thereby treating the disease associated with intestinal barrier dysfunction.
A method of treating a disease associated with intestinal barrier dysfunction in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an agent which decreases the amount and/or activity of at least one agent set forth in Table 3, thereby treating the disease associated with intestinal barrier dysfunction.
A co-culture system comprising cells of a tissue derived from a subject and microbes derived from a microbiome of said tissue of said subject.
Dependencies are inferred from the claim text.